O	0	4	Dose
O	4	5	-
O	5	13	Response
O	14	21	Effects
O	22	24	of
B-intervention	25	30	Acute
I-intervention	31	38	Aerobic
I-intervention	39	47	Exercise
I-intervention	48	56	Duration
O	57	59	on
O	60	69	Cognitive
O	70	78	Function
O	79	81	in
B-eligibility	82	90	Patients
I-eligibility	91	95	With
I-eligibility	96	102	Breast
I-eligibility	103	109	Cancer
O	109	110	:
O	111	112	A
O	113	123	Randomized
O	124	133	Crossover
O	134	139	Trial
O	139	140	.

O	141	143	To
O	144	151	examine
O	152	155	the
O	156	168	differential
O	169	176	effects
O	177	179	of
O	180	185	acute
O	186	194	exercise
O	195	203	duration
O	204	206	on
O	207	214	domains
O	215	217	of
O	218	227	executive
O	228	236	function
O	237	240	and
O	241	251	processing
O	252	257	speed
O	258	260	in
O	261	269	patients
O	270	274	with
O	275	281	breast
O	282	288	cancer
O	288	289	.

O	290	302	Participants
O	303	304	(
O	304	305	N
O	306	307	=
B-total-participants	308	310	48
O	310	311	,
B-age	312	316	Mage
I-age	317	318	=
I-age	319	321	56
I-age	321	322	.
I-age	322	324	02
I-age	325	326	Â±
I-age	327	329	10
I-age	329	330	.
I-age	330	332	99
O	332	333	)
O	334	343	completed
O	344	347	two
O	348	356	sessions
O	357	359	in
O	360	375	counterbalanced
O	376	381	order
O	381	382	:
O	383	391	moderate
O	391	392	-
O	392	401	intensity
O	402	411	treadmill
O	412	419	walking
O	420	423	and
O	424	431	sitting
O	431	432	.

O	433	445	Participants
O	446	450	were
O	451	455	also
O	456	466	randomized
O	467	469	to
O	470	473	one
O	474	476	of
O	477	482	three
O	483	491	duration
O	492	502	conditions
O	502	503	:
O	504	506	10
O	507	508	(
O	508	509	n
O	510	511	=
B-intervention-participants	512	514	15
O	514	515	)
O	515	516	,
O	517	519	20
O	520	521	(
O	521	522	n
O	523	524	=
B-intervention-participants	525	527	16
O	527	528	)
O	528	529	,
O	530	532	or
O	533	535	30
O	536	537	(
O	537	538	n
O	539	540	=
B-intervention-participants	541	543	17
O	543	544	)
O	545	548	min
O	548	549	,
O	550	560	reflecting
O	561	564	the
O	565	571	length
O	572	574	of
O	575	579	time
O	580	585	spent
O	586	593	walking
O	594	597	and
O	598	605	sitting
O	605	606	.

O	607	618	Immediately
O	619	625	before
O	626	629	and
O	630	635	after
O	636	640	each
O	641	648	session
O	648	649	,
O	650	655	women
O	656	665	completed
O	666	667	a
O	668	675	battery
O	676	678	of
O	679	688	cognitive
O	689	694	tasks
O	695	696	(
O	696	697	e
O	697	698	.
O	698	699	g
O	699	700	.
O	700	701	,
O	702	712	inhibition
O	712	713	,
O	714	723	cognitive
O	724	735	flexibility
O	735	736	,
O	737	744	spatial
O	745	752	working
O	753	759	memory
O	759	760	,
O	761	764	and
O	765	775	processing
O	776	781	speed
O	781	782	)
O	782	783	.

O	784	790	Within
O	790	791	-
O	792	795	and
O	796	803	between
O	803	804	-
O	804	812	subjects
O	813	821	repeated
O	821	822	-
O	822	830	measures
O	831	839	analyses
O	840	842	of
O	843	851	variance
O	852	860	revealed
O	861	865	time
O	866	868	by
O	869	878	condition
O	879	891	interactions
O	892	894	on
O	895	899	both
O	900	910	processing
O	911	916	speed
O	917	918	(
O	918	919	p
O	920	921	=
O	922	923	0
O	923	924	.
O	924	926	02
O	926	927	)
O	928	931	and
B-outcome	932	939	spatial
I-outcome	940	947	working
I-outcome	948	954	memory
O	955	956	(
O	956	958	ps
O	959	960	<
O	961	962	0
O	962	963	.
O	963	965	07
O	965	966	)
O	966	967	,
O	968	972	such
O	973	977	that
O	978	983	women
O	984	996	demonstrated
O	997	1005	improved
O	1006	1015	cognitive
O	1016	1027	functioning
O	1028	1038	regardless
O	1039	1041	of
O	1042	1045	the
O	1046	1050	time
O	1051	1056	spent
O	1057	1064	walking
O	1064	1065	.

O	1066	1071	There
O	1072	1076	were
O	1077	1081	also
O	1082	1089	several
O	1090	1100	moderately
O	1101	1106	sized
O	1107	1112	three
O	1112	1113	-
O	1113	1116	way
O	1117	1118	(
O	1118	1119	e
O	1119	1120	.
O	1120	1121	g
O	1121	1122	.
O	1122	1123	,
O	1124	1128	time
O	1129	1131	by
O	1132	1141	condition
O	1142	1144	by
O	1145	1153	duration
O	1153	1154	)
O	1155	1167	interactions
O	1168	1174	driven
O	1175	1177	by
B-outcome	1178	1186	declines
I-outcome	1187	1189	in
I-outcome	1190	1199	cognitive
I-outcome	1200	1211	functioning
O	1212	1217	after
O	1218	1225	sitting
O	1226	1228	on
O	1229	1238	cognitive
O	1239	1250	flexibility
O	1251	1253	in
O	1254	1257	the
O	1258	1260	10
O	1261	1262	(
O	1262	1263	d
O	1264	1265	=
O	1266	1267	-
O	1267	1268	0
O	1268	1269	.
O	1269	1271	96
O	1271	1272	)
O	1273	1276	and
O	1277	1279	30
O	1279	1280	-
O	1280	1283	min
O	1284	1285	(
O	1285	1286	d
O	1287	1288	=
O	1289	1290	-
O	1290	1291	0
O	1291	1292	.
O	1292	1294	52
O	1294	1295	)
O	1296	1302	groups
O	1303	1306	and
O	1307	1317	inhibition
O	1318	1320	in
O	1321	1324	the
O	1325	1327	20
O	1327	1328	-
O	1328	1331	min
O	1332	1337	group
O	1338	1339	(
O	1339	1340	d
O	1341	1342	=
O	1343	1344	0
O	1344	1345	.
O	1345	1347	75
O	1347	1348	)
O	1348	1349	.

O	1350	1352	On
O	1353	1356	the
O	1357	1367	processing
O	1368	1373	speed
O	1374	1378	task
O	1378	1379	,
O	1380	1385	women
B-outcome	1386	1395	performed
I-outcome	1396	1409	significantly
I-outcome	1410	1416	faster
I-outcome	1417	1422	after
I-outcome	1423	1430	walking
O	1431	1439	compared
O	1440	1444	with
O	1445	1450	after
O	1451	1458	sitting
O	1459	1461	in
O	1462	1465	the
O	1466	1468	20
O	1468	1469	-
O	1469	1472	min
O	1473	1478	group
O	1479	1480	(
O	1480	1481	d
O	1482	1483	=
O	1484	1485	-
O	1485	1486	0
O	1486	1487	.
O	1487	1489	24
O	1489	1490	)
O	1490	1491	.

O	1492	1495	For
O	1496	1502	select
O	1503	1512	cognitive
O	1513	1520	domains
O	1520	1521	,
O	1522	1529	walking
O	1530	1538	anywhere
O	1539	1543	from
O	1544	1546	10
O	1547	1549	to
O	1550	1552	30
O	1553	1556	min
O	1557	1559	is
O	1560	1570	associated
O	1571	1575	with
O	1576	1587	significant
O	1588	1596	benefits
O	1596	1597	.

O	1598	1601	Our
O	1602	1610	findings
O	1611	1618	suggest
O	1619	1622	the
O	1623	1627	need
O	1628	1631	for
O	1632	1639	further
O	1640	1648	research
O	1649	1653	into
O	1654	1657	the
O	1658	1668	mechanisms
O	1669	1672	and
O	1673	1677	dose
O	1677	1678	-
O	1678	1686	response
O	1687	1700	relationships
O	1701	1708	between
O	1709	1714	acute
O	1715	1723	exercise
O	1724	1727	and
O	1728	1737	cognition
O	1738	1740	as
O	1741	1745	well
O	1746	1748	as
O	1749	1752	how
O	1753	1757	such
O	1758	1763	acute
O	1764	1769	bouts
O	1770	1773	may
O	1774	1776	be
O	1777	1788	accumulated
O	1789	1792	for
O	1793	1799	larger
O	1799	1800	,
O	1801	1808	lasting
O	1809	1818	cognitive
O	1819	1827	benefits
O	1828	1833	after
O	1834	1840	breast
O	1841	1847	cancer
O	1847	1848	.
O	1849	1852	www
O	1852	1853	.
O	1853	1867	ClinicalTrials
O	1867	1868	.
O	1868	1871	gov
O	1871	1872	,
O	1873	1883	identifier
O	1884	1895	NCT04255225
O	1895	1896	.
